Xenon Pharmaceuticals (XENE) Earnings Analysis
Xenon Pharmaceuticals (XENE) next reports earnings on 2026-08-10, consensus EPS -1.16 USD. Last quarter (2026-05-07) it beat with EPS -1.17 USD vs -1.17 USD est (0%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -14.08.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does XENE next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -1.16 USD |
| Revenue estimate | 0.00B |
XENE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -1.17 USD | -1.17 USD | 0% | Beat |
| 2026-02-26 | -1.31 USD | -1.2 USD | -9.2% | Miss |
| 2025-11-03 | -1.15 USD | -1.16 USD | +0.9% | Beat |
| 2025-08-11 | -1.07 USD | -1.03 USD | -3.9% | Miss |
| 2025-05-12 | -0.83 USD | -0.94 USD | +11.7% | Beat |
| 2025-02-27 | -0.84 USD | -0.89 USD | +5.6% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
XENE valuation and analyst view
| Trailing P/E | -14.08 |
|---|---|
| Trailing EPS | -4.38676 USD |
| Price / book | 4.32 |
| Dividend yield | 0.00% |
| Market cap | 5.24B |
| Analyst consensus | Buy (22 buy / 0 hold / 0 sell) |
| Avg price target | 73.5 USD |
Related research pages
Frequently asked questions
When is Xenon Pharmaceuticals (XENE)'s next earnings date?
Xenon Pharmaceuticals is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -1.16 USD and revenue estimate of 0.00B.
Did XENE beat earnings last quarter?
In its 2026-05-07 report, XENE posted EPS of -1.17 USD versus a -1.17 USD estimate — a beat of 0%.
What is XENE's earnings track record?
Over the last 6 reported quarters with consensus data, XENE beat estimates 4 times (67%).
What is XENE's current P/E ratio and EPS?
XENE trades at a trailing P/E of -14.08 on trailing EPS of -4.386763463170152 USD.
What do analysts rate XENE?
Analyst consensus is "Buy" across 22 ratings (0 strong buy, 22 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 73.5 USD.